ERBB2 and gastroesophageal junction adenocarcinoma: The SPOTLIGHT trial evaluated the efficacy and safety of ZOL-FO as a first-line regimen for the treatment of CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma (Shitara et al., 2023).